Opinion statement Well-to moderately differentiated neuroendocrine tumors (NET) are a
heterogeneous group of malignancies for which a range of therapeutic options have been …

Neuroendocrine tumors (NETs) occur throughout the body, and share similar histologic
characteristics. However, it has become increasingly evident that pancreatic NETs tend to …

Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and
pancreatic NETs (pancNETs). Although these tumors share many morphologic and clinical …

Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with
symptoms of hormone secretion may require specific medical interventions to control those …

Purpose There are few effective therapies for pancreatic neuroendocrine tumors (PNETs).
Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) …

Neuroendocrine tumors (NETs) are rare tumors that have been increasing in incidence over
the last 30 years with no significant changes in survival. As survival of patients with these …

Neuroendocrine tumors (NETs) describe a heterogeneous group of tumors with a wide
range of morphologic, functional, and behavioral characteristics. These tumors are generally …

Neuroendocrine tumors (NET) are frequently diagnosed late and not amenable to curative
surgery due to metastatic disease to the liver and lymph nodes. The disease is complex and …

Neuroendocrine tumors (NETs) are heterogeneous in underlying tumor biology and clinical
presentations. They are generally classified according to their degree of differentiation and …

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to
cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial …